GE HealthCare Completes Phase I Clinical Programme for Macrocyclic MRI Contrast Agent

GE HealthCare completes phase I clinical development programme for a first-of-its-kind manganese-based macrocyclic MRI contrast agent

Overview

GE HealthCare, a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, has announced the completion of its phase I clinical development programme for a first-of-its-kind manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. The results, which will be used to support ongoing clinical development, concluded that in a first-in-human study, this manganese-based contrast agent was well tolerated with no serious adverse events, dose-limiting toxicities or clinically relevant findings reported, according to an abstract presented at the 2024 bi-annual Contrast Media Research symposium in Oslo, Norway.

About MRI Contrast Agents

• MRI contrast agents, which are typically gadolinium-based, are used to enhance visualization of abnormal structures or lesions and to aid differentiation between healthy and pathological tissue. 
• This macrocyclic, extra-cellular, general-purpose, manganese-based contrast agent has comparable relaxivity (the ability to enhance signal intensity) to gadolinium-based agents and is expected to be diagnostically similar to current gadolinium-based products. 
• Unlike gadolinium, manganese is naturally occurring in - and efficiently eliminated - from the body. 
• Along with its suitable image-enhancing properties, this manganese-based agent could be a viable alternative to gadolinium, particularly in light of perceived concerns relating to gadolinium retention and the potential impact of post-patient excreted gadolinium in the environment.

Statement from GE HealthCare

Dr Paul Evans, head of global R&D at GE HealthCare’s Pharmaceutical Diagnostics business segment, said, “These are encouraging phase I results for this manganese-based contrast agent and we look forward to completing the next steps in the clinical development process. This is part of our pipeline of products aiming to improve patient outcomes across care pathways.

Statement from the Mayo Clinic: Dr Robert J. McDonald

Dr Robert J. McDonald, Radiologist at Mayo Clinic and Contrast Media Safety Committee Board member for the American College of Radiology, whose group has collaborated with GE HealthCare during the research phase, commented, “GE HealthCare’s manganese-based contrast agent could offer benefits such as reduced risk of tissue deposition and improved safety for certain vulnerable patient populations compared to gadolinium-based agents, while also providing comparable imaging capabilities and potentially lower environmental impact.

About phase I trial & • GE HealthCare

• The phase I trial was undertaken at the clinical research unit at Oslo University Hospital, Rikshospitalet, Norway, and benefited from partial funding provided by the Norwegian Research Council. 
• GE HealthCare has two contrast media facilities in Norway. 
• One site in Oslo, where this manganese-based contrast agent was developed, is celebrating its 150-year anniversary this year. 
• In addition, GE HealthCare’s active pharmaceutical ingredients (API) manufacturing site in Lindesnes, southern Norway, is celebrating its 50th year of production.

Words from the CEO: GE HealthCare

Kevin O’Neill, president and CEO of GE HealthCare’s Pharmaceutical Diagnostics segment, added, “As we celebrate milestone anniversaries for these two facilities, the phase I results are a reminder of Norway’s heritage of innovation that has shaped the field of diagnostic imaging, improving patient outcomes worldwide. We aim to offer more choice to radiologists, delivering a broad portfolio that can enable personalized care and address unmet patient needs.

Pharmaceutical Diagnostics Unit

• GE HealthCare’s Pharmaceutical Diagnostics unit is a global leader in imaging agents used to support 120 million procedures per year globally, equivalent to four patient procedures every second. 
• For more than 40 years, GE HealthCare contrast media has been routinely used across MRI, X-ray/CT and ultrasound to enhance clinical images and support diagnosis.

About the Compound: GE HealthCare

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!